FHL2, Human, mAb F4B2-B11
The monoclonal antibody F4B2-B11 reacts specifically with the LIM-only protein FHL2. Five proteins share the same structural organization and a high degree of sequence homology in this group: four and a half LIM domain protein (FHL) 1, FHL2, FHL3, FHL4, and activator of cAMP-responsive element (CRE) modulator (CREM) in testis (ACT). LIM domains are constituted by a conserved cysteine- and histidine-rich structure shaped in two repeated zinc fingers first identified in the proteins encoded by the Lin-11, Isl-1, and Mec-3 genes. The LIM domain has been shown to function as a protein-protein interaction domain, and has often been described in association with other functional protein motifs, such as homeobox and kinase domains. FHL2 seems to be a promiscuous coactivator because it modulates the activity of the androgen receptor, CRE-binding protein (CREB), and WT1, although some degree of specificity is present because it is unable to stimulate CREM- and Sp1-dependent transcription. FHL2 expression was originally described to be restricted to the heart but it is inducible in other cell types. FHL2 shows specific interaction with beta-catenin, which requires the intact structure of all four LIM domains of FHL2 and the N-terminus plus the first armadillo repeat region of beta-catenin. FHL2 is a muscle-specific repressor of LEF/TCF target genes and promotes myogenic differentiation by interacting with beta-catenin. Monoclonal antibody F4B2-B11 recognizes the N-terminal Zn-Finger motif, it does not crossreact in Western Blotting with the FHL1 and FHL3 proteins. The F4B2-B11 antibody is cross reactive with mouse and rat FHL2.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA